Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Driven by chemistry but increasingly guided by pharmacology and
the clinical sciences, drug research has contributed moreto the
progress of medicine during the past century than any otherscientific
factor. The advent of molecular biology and, in particular,of genomic
sciences is having a deep impact on drug discovery.Recombinant
proteins and monoclonal antibodies have greatly enrichedour
therapeutic armamentarium. Genome sciences, combined withbioinformatic
tools, allow us to dissect the genetic basis ofmultifactorial diseases
and to determine the most suitable pointsof attack for future
medicines, thereby increasing the numberof treatment options. The
dramatic increase in the complexityof drug research is enforcing
changes in the institutional basisof this interdisciplinary endeavor.
The biotech industry is establishingitself as the discovery arm of the
pharmaceutical industry. Inbridging the gap between academia and large
pharmaceutical companies,the biotech firms have been effective
instruments of technologytransfer.
International Biomedicine Management Partners, Basel, Switzerland
and Orbimed Advisors LLC, New York, NY 10017-2023, USA.
The editors suggest the following Related Resources on Science sites:
In Science Magazine
LETTERS
Manuel A. Navia and Jürgen Drews (23 June 2000) Science288 (5474), 2132.
[DOI: 10.1126/science.288.5474.2132] |Full Text »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A New Simple Cell-Based Homogeneous Time-Resolved Fluorescence QRET Technique for Receptor-Ligand Interaction Screening.
H. Harma, A. Rozwandowicz-Jansen, E. Martikkala, H. Frang, I. Hemmila, N. Sahlberg, V. Fey, M. Perala, and P. Hanninen (2009)
J Biomol Screen
14, 936-943
|Abstract »|PDF »
Systematizing Serendipity for Cardiovascular Drug Discovery.
P. J. Schlueter and R. T. Peterson (2009)
Circulation
120, 255-263
|Full Text »|PDF »
Testing the druggable endothelial differentiation gene 2 knee osteoarthritis genetic factor for replication in a wide range of sample collections.
R Dieguez-Gonzalez, M Calaza, D Shi, I Meulenbelt, J Loughlin, A Tsezou, J Dai, K N Malizos, E P Slagboom, M Kloppenburg, et al. (2009)
Ann Rheum Dis
68, 1017-1021
|Abstract »|Full Text »|PDF »
Properties and identification of human protein drug targets.
Duplexed Label-Free G Protein--Coupled Receptor Assays for High-Throughput Screening.
E. Tran and Ye Fang (2008)
J Biomol Screen
13, 975-985
|Abstract »|PDF »
Contrasting the resource-based view and competitiveness theories: how pharmaceutical firms choose to compete in Germany, Italy and the UK.
A. M. Herrmann (2008)
Strategic Organization
6, 343-374
|Abstract »|PDF »
Metadegradomics: Toward in Vivo Quantitative Degradomics of Proteolytic Post-translational Modifications of the Cancer Proteome.
A. Doucet, G. S. Butler, D. Rodriguez, A. Prudova, and C. M. Overall (2008)
Mol. Cell. Proteomics
7, 1925-1951
|Abstract »|Full Text »|PDF »
Mutations in a Molecule: The Virtues of Antagonism.
E. D. Kharasch (2008)
Mayo Clin. Proc.
83, 1083-1086
|Full Text »|PDF »
In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti-HIV Activity of Aplaviroc.
J. F. Demarest, S. S. Sparks, K. Schell, S. Shibayama, C. B. McDanal, L. Fang, K. K. Adkison, A. Shachoy-Clark, and S. C. Piscitelli (2008)
J. Clin. Pharmacol.
48, 1179-1188
|Abstract »|Full Text »|PDF »
Characterization of an Orphan G Protein-coupled Receptor, GPR20, That Constitutively Activates Gi Proteins.
M. Hase, T. Yokomizo, T. Shimizu, and M. Nakamura (2008)
J. Biol. Chem.
283, 12747-12755
|Abstract »|Full Text »|PDF »
Rear-view Mirrors and Crystal Balls: A Brief Reflection on Drug Discovery.
Alternative splicing of the G protein-coupled receptor superfamily in human airway smooth muscle diversifies the complement of receptors.
R. Einstein, H. Jordan, W. Zhou, M. Brenner, E. G. Moses, and S. B. Liggett (2008)
PNAS
105, 5230-5235
|Abstract »|Full Text »|PDF »
Structure of the Complement Factor 5a Receptor-Ligand Complex Studied by Disulfide Trapping and Molecular Modeling.
I. S. Hagemann, D. L. Miller, J. M. Klco, G. V. Nikiforovich, and T. J. Baranski (2008)
J. Biol. Chem.
283, 7763-7775
|Abstract »|Full Text »|PDF »
A nanostructure-initiator mass spectrometry-based enzyme activity assay.
T. R. Northen, J.-C. Lee, L. Hoang, J. Raymond, D.-R. Hwang, S. M. Yannone, C.-H. Wong, and G. Siuzdak (2008)
PNAS
105, 3678-3683
|Abstract »|Full Text »|PDF »
Quantitative systems-level determinants of human genes targeted by successful drugs.
High-Resolution Crystal Structure of an Engineered Human 2-Adrenergic G Protein Coupled Receptor.
V. Cherezov, D. M. Rosenbaum, M. A. Hanson, S. G. F. Rasmussen, F. S. Thian, T. S. Kobilka, H.-J. Choi, P. Kuhn, W. I. Weis, B. K. Kobilka, et al. (2007)
Science
318, 1258-1265
|Abstract »|Full Text »|PDF »
The conformation of acetylcholine at its target site in the membrane-embedded nicotinic acetylcholine receptor.
P. T. F. Williamson, A. Verhoeven, K. W. Miller, B. H. Meier, and A. Watts (2007)
PNAS
104, 18031-18036
|Abstract »|Full Text »|PDF »
A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule.
J.-P. Liou, K.-S. Hsu, C.-C. Kuo, C.-Y. Chang, and J.-Y. Chang (2007)
J. Pharmacol. Exp. Ther.
323, 398-405
|Abstract »|Full Text »|PDF »
LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake.
Z. Zhou, J. Zhen, N. K. Karpowich, R. M. Goetz, C. J. Law, M. E. A. Reith, and D.-N. Wang (2007)
Science
317, 1390-1393
|Abstract »|Full Text »|PDF »
A modular instrument for exploring the mechanics of cardiac myocytes.
M. G. Garcia-Webb, A. J. Taberner, N. C. Hogan, and I. W. Hunter (2007)
Am J Physiol Heart Circ Physiol
293, H866-H874
|Abstract »|Full Text »|PDF »
Atherosclerosis: The Path From Genomics to Therapeutics.
D. T. Miller, P. M. Ridker, P. Libby, and D. J. Kwiatkowski (2007)
J. Am. Coll. Cardiol.
49, 1589-1599
|Abstract »|Full Text »|PDF »
The First Extracellular Loop of the Saccharomyces cerevisiae G Protein-coupled Receptor Ste2p Undergoes a Conformational Change upon Ligand Binding.
M. Hauser, S. Kauffman, B.-K. Lee, F. Naider, and J. M. Becker (2007)
J. Biol. Chem.
282, 10387-10397
|Abstract »|Full Text »|PDF »
The Highly Conserved DRY Motif of Class A G Protein-Coupled Receptors: Beyond the Ground State.
G. E. Rovati, V. Capra, and R. R. Neubig (2007)
Mol. Pharmacol.
71, 959-964
|Abstract »|Full Text »|PDF »
ZM241385, DPCPX, MRS1706 Are Inverse Agonists with Different Relative Intrinsic Efficacies on Constitutively Active Mutants of the Human Adenosine A2B Receptor.
Q. Li, K. Ye, C. C. Blad, H. den Dulk, J. Brouwer, A. P. IJzerman, and M. W. Beukers (2007)
J. Pharmacol. Exp. Ther.
320, 637-645
|Abstract »|Full Text »|PDF »
Nanoliter microfluidic hybrid method for simultaneous screening and optimization validated with crystallization of membrane proteins.
L. Li, D. Mustafi, Q. Fu, V. Tereshko, D. L. Chen, J. D. Tice, and R. F. Ismagilov (2006)
PNAS
103, 19243-19248
|Abstract »|Full Text »|PDF »
A New Mechanism of Methotrexate Action Revealed by Target Screening with Affinity Beads.
H. Uga, C. Kuramori, A. Ohta, Y. Tsuboi, H. Tanaka, M. Hatakeyama, Y. Yamaguchi, T. Takahashi, M. Kizaki, and H. Handa (2006)
Mol. Pharmacol.
70, 1832-1839
|Abstract »|Full Text »|PDF »
Universal Screening Methods and Applications of ThermoFluor(R).
M. D. Cummings, M. A. Farnum, and M. I. Nelen (2006)
J Biomol Screen
11, 854-863
|Abstract »|PDF »
Identification of specific gene expression profiles in fibroblasts derived from middle ear cholesteatoma..
M. Yoshikawa, H. Kojima, K. Wada, T. Tsukidate, N. Okada, H. Saito, and H. Moriyama (2006)
Arch Otolaryngol Head Neck Surg
132, 734-742
|Abstract »|Full Text »|PDF »
From genomics to drug targets.
S. G. Dahl and I. Sylte (2006)
J Psychopharmacol
20, 95-99
|Abstract »|PDF »
Therapeutic targets: progress of their exploration and investigation of their characteristics..
C. J. Zheng, L. Y. Han, C. W. Yap, Z. L. Ji, Z. W. Cao, and Y. Z. Chen (2006)
Pharmacol. Rev.
58, 259-279
|Abstract »|Full Text »|PDF »
Statistical analysis and prediction of functional residues effective for GPCR-G-protein coupling selectivity.
Discovery and Characterization of Orthosteric and Allosteric Muscarinic M2 Acetylcholine Receptor Ligands by Affinity Selection-Mass Spectrometry.
C. E. Whitehurst, N. Nazef, D. A. Annis, Y. Hou, D. M. Murphy, P. Spacciapoli, Z. Yao, M. R. Ziebell, C. C. Cheng, G. W. Shipps Jr., et al. (2006)
J Biomol Screen
11, 194-207
|Abstract »|PDF »
Screening phage display libraries for organ-specific vascular immunotargeting in vivo.
P. Valadon, J. D. Garnett, J. E. Testa, M. Bauerle, P. Oh, and J. E. Schnitzer (2006)
PNAS
103, 407-412
|Abstract »|Full Text »|PDF »
An Optimized Strategy for ICAT Quantification of Membrane Proteins.
C. Ramus, A. G. de Peredo, C. Dahout, M. Gallagher, and J. Garin (2006)
Mol. Cell. Proteomics
5, 68-78
|Abstract »|Full Text »|PDF »
Neuropeptide S and Its Receptor: A Newly Deorphanized G Protein-Coupled Receptor System.
R. K. Reinscheid and Y.-L. Xu (2005)
Neuroscientist
11, 532-538
|Abstract »|PDF »
Realizing the Promise of Genomics in Biomedical Research.
A. E. Guttmacher and F. S. Collins (2005)
JAMA
294, 1399-1402
|Full Text »|PDF »
A Peptide Core Motif for Binding to Heterotrimeric G Protein {alpha} Subunits.
W. W. Ja, A. Adhikari, R. J. Austin, S. R. Sprang, and R. W. Roberts (2005)
J. Biol. Chem.
280, 32057-32060
|Abstract »|Full Text »|PDF »
ChemMine. A Compound Mining Database for Chemical Genomics.
T. Girke, L.-C. Cheng, and N. Raikhel (2005)
Plant Physiology
138, 573-577
|Full Text »|PDF »
Molecular Mechanism Underlying Partial and Full Agonism Mediated by the Human Cholecystokinin-1 Receptor.
E. Archer-Lahlou, C. Escrieut, P. Clerc, J. Martinez, L. Moroder, C. Logsdon, A. Kopin, C. Seva, M. Dufresne, L. Pradayrol, et al. (2005)
J. Biol. Chem.
280, 10664-10674
|Abstract »|Full Text »|PDF »
Identification of RAI3 as a therapeutic target for breast cancer.
T Nagahata, T Sato, A Tomura, M Onda, K Nishikawa, and M Emi (2005)
Endocr. Relat. Cancer
12, 65-73
|Abstract »|Full Text »|PDF »
Neuropeptide S: A New Player in the Modulation of Arousal and Anxiety.
Regulation of M2 Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators.
L. T. May, Y. Lin, P. M. Sexton, and A. Christopoulos (2005)
J. Pharmacol. Exp. Ther.
312, 382-390
|Abstract »|Full Text »|PDF »
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects.
S. A. Qureshi, M. Rios Candelore, D. Xie, X. Yang, L. M. Tota, V. D.-H. Ding, Z. Li, A. Bansal, C. Miller, S. M. Cohen, et al. (2004)
Diabetes
53, 3267-3273
|Abstract »|Full Text »|PDF »
Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis.
C. Lefevre, B. Bouadjar, A. Karaduman, F. Jobard, S. Saker, M. Ozguc, M. Lathrop, J.-F. Prud'homme, and J. Fischer (2004)
Hum. Mol. Genet.
13, 2473-2482
|Abstract »|Full Text »|PDF »
The C-terminal Nonapeptide of Mature Chemerin Activates the Chemerin Receptor with Low Nanomolar Potency.
V. Wittamer, F. Gregoire, P. Robberecht, G. Vassart, D. Communi, and M. Parmentier (2004)
J. Biol. Chem.
279, 9956-9962
|Abstract »|Full Text »|PDF »
Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors.
V. Avlani, L. T. May, P. M. Sexton, and A. Christopoulos (2004)
J. Pharmacol. Exp. Ther.
308, 1062-1072
|Abstract »|Full Text »|PDF »
Constitutively active Gq/11-coupled Receptors Enable Signaling by Co-expressed Gi/o-coupled Receptors.
R. A. Bakker, P. Casarosa, H. Timmerman, M. J. Smit, and R. Leurs (2004)
J. Biol. Chem.
279, 5152-5161
|Abstract »|Full Text »|PDF »
A phage-displayed peptide can inhibit infection by white spot syndrome virus of shrimp.
LSSIG is a novel murine leukocyte-specific GPCR that is induced by the activation of STAT3.
T. Senga, S. Iwamoto, T. Yoshida, T. Yokota, K. Adachi, E. Azuma, M. Hamaguchi, and T. Iwamoto (2003)
Blood
101, 1185-1187
|Abstract »|Full Text »|PDF »
External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator.
S. Asada, Y. Choi, M. Yamada, S.-C. Wang, M.-C. Hung, J. Qin, and M. Uesugi (2002)
PNAS
99, 12747-12752
|Abstract »|Full Text »|PDF »
A novel medium throughput quantitative competitive PCR technology to simultaneously measure mRNA levels from multiple genes.
Drowning in the Magic Well: Shaman Pharmaceuticals and the Elusive Value of Traditional Knowledge.
R. A. Clapp and C. Crook (2002)
The Journal of Environment Development
11, 79-102
|Abstract »|PDF »
Profiling Novel Sulfonamide Antitumor Agents with Cell-based Phenotypic Screens and Array-based Gene Expression Analysis.
A. Yokoi, J. Kuromitsu, T. Kawai, T. Nagasu, N. Hata Sugi, K. Yoshimatsu, H. Yoshino, and T. Owa (2002)
Mol. Cancer Ther.
1, 275-286
|Abstract »|Full Text »|PDF »
Evolution of Anticancer Drug Discovery and the Role of Cell-Based Screening.
F. M. Balis (2002)
J Natl Cancer Inst
94, 78-79
|Full Text »|PDF »
Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells.
M. E. Burczynski, M. McMillian, J. Ciervo, L. Li, J. B. Parker, R. T. Dunn II, S. Hicken, S. Farr, and M. D. Johnson (2000)
Toxicol. Sci.
58, 399-415
|Abstract »|Full Text »|PDF »
